Eli Lilly, Incyte Say FDA Grants EUA for Baricitinib
November 19 2020 - 6:14PM
Dow Jones News
By Stephen Nakrosis
Eli Lilly and Co. and Incyte on Thursday said the U.S. Food and
Drug Administration issued an emergency use authorization for
Baricitinib to treat hospitalized patients with Covid-19.
The EUA "enables use of baricitinib in combination with
remdesivir in hospitalized patients needing oxygen," the companies
said.
The EUA is based on data from the Adaptive COVID-19 Treatment
Trial conducted by the National Institute of Allergy and Infectious
Diseases, part of the National Institutes of Health, the companies
said. Among the findings, the companies said were that "patients
treated with baricitinib in combination with remdesivir had a
significant reduction in median time to recovery from 8 to 7 days
compared to remdesivir," and "patients treated with baricitinib in
combination with remdesivir were more likely to have a better
clinical status at Day 15 compared to patients treated with
remdesivir."
Baricitinib is an oral JAK inhibitor that was discovered by
Incyte and licensed to Lilly, the companies said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 19, 2020 17:59 ET (22:59 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Oct 2023 to Oct 2024